H. Lundbeck A/S announced that following the resignation of Kåre Schultz (President and CEO) and Staffan Schüberg (EVP and Chief Commercial Officer) announced on September 11, 2017 the board of directors of the company has decided that as of November 1, 2017 Anders Götzsche (EVP and CFO) will take over the operational management of the company as interim CEO. Both Kåre Schultz and Staffan Schüberg will have their last day in the company on October 31, 2017. At the same time, Lundbeck's current President of Lundbeck North America, Peter Anastasiou, will join the Executive Management team while maintaining his responsibility for Commercial Operations in North America.

Jacob Tolstrup will be responsible for Commercial Operations in Europe, International Markets, Global Marketing and Corporate Business Development. Peter Anastasiou serves as President of Lundbeck North America, overseeing the operations of both the U.S. and Canadian businesses. Peter Anastasiou has been with Lundbeck since 2009 and has since early 2016 served as President of Lundbeck U.S. where he oversees all aspects of the U.S value chain, directing all Commercial, Drug Development and Corporate activities.

Prior to that he served as U.S. Chief Commercial Officer, during which time he directed the Commercial operations of the company's Psychiatry and Neurology franchises.